Open AccessEyelashes trichomegaly: An unusual side effect of gefitinib therapy
Author(s) -
Chaturbhuj Agrawal,
Pankaj Goyal,
Dinesh Chandra Doval,
Kumardeep Dutta,
Kshitij Domadia,
Silky Kothiwal
Publication year - 2018
Publication title -
international journal of trichology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.494
H-Index - 22
eISSN - 0974-9241
pISSN - 0974-7753
DOI - 10.4103/ijt.ijt_72_17
Subject(s) - gefitinib , medicine , side effect (computer science) , lung cancer , diarrhea , oncology , cancer , epidermal growth factor receptor , combination therapy , targeted therapy , intensive care medicine , computer science , programming language
Evolution of targeted therapy has changed the spectrum of treatment in oncology since the past two decades as lots of newer agents are being added to the pharmacologic armamentarium of cancer therapy. Epidermal growth factor receptor inhibitors form one such advancing field with many newer agents being investigated and they are used in wide variety of malignancies such as head and neck cancer, lung cancer, and even gastrointestinal malignancies such as pancreatic cancer. Various troublesome side effects of these agents include diarrhea, severe fatigability, severe skin rashes, and deranged liver function tests which may require treatment interruption or dose reduction resulting in decreased response to treatment. However, some of the side effects may not require dose modification but incidentally observed and does not impact patient's quality of life. One such effect is trichomegaly which is very rarely observed with such agents. Herein, this conversation we report a 52-year-old female case of metastatic carcinoma lung who developed trichomegaly of eyelashes while on gefitinib therapy.